Helus Pharma Inc.

HELP Nasdaq SEC CIK 1833141
Follow Helus Pharma Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 CAD · IFRS
Net income −CAD 113.1M −44.9% vs prior year
EPS, diluted −CAD 5.59 +40.6% vs prior year
Operating cash flow −CAD 101.3M −47% vs prior year
Revenue by fiscal year
CAD 864K
CAD 0
FY21 FY22

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income6 fiscal years
−CAD 150M−CAD 100M−CAD 50MCAD 0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−CAD 113.1M
FY24−CAD 78.1M
FY23−CAD 47.5M
FY22−CAD 67.6M
FY21−CAD 32.2M
FY20-
Free cash flowOperating cash flow minus capital expenditure
−CAD 80M−CAD 60M−CAD 40M−CAD 20MCAD 0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−CAD 68.9M
FY23−CAD 47.6M
FY22−CAD 45.3M
FY21−CAD 19.2M
FY20-